Skip to main content

Bipolar Disorders

March 06, 2020
In this occasional feature, members of the Psych Congress Steering Committee and faculty answer questions asked by attendees at Psych Congress meetings. QUESTION: What criteria differentiates between bipolar disorder with psychotic features and the bipolar type of schizoaffective…
January 29, 2020
The US Food and Drug Administration (FDA) has accepted Alkermes’ New Drug Application (NDA) for ALKS 3831, a combination of olanzapine and samidorphan, the company announced.
January 24, 2020
An interactive voice application’s assessment of patient well-being through analysis of their speech was highly comparable with physicians’ tracking of patient well-being, according to a study published online in PLOS One.
January 20, 2020
Psych Congress Steering Committee member Vladimir Maletic, MD, MS, discusses how frequently patients can cycle between depression and mania.
November 19, 2019
Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of the investigational drug ALKS 3831, a combination of the antipsychotic olanzapine and samidorphan, a novel molecular entity.
October 15, 2019
The risk for Parkinson disease appears to be much higher in people with bipolar disorder than in the general population, according to a systematic review and meta-analysis.
October 05, 2019
SAN DIEGO—Children with bipolar disorder who were treated with lurasidone had a lower risk of all-cause and psychiatric-related hospitalization than those treated with aripiprazole or olanzapine, according to a retrospective claims database study.
October 04, 2019
SAN DIEGO—Side effects were experienced nearly universally by respondents in an online survey who took oral antipsychotics the previous year for bipolar I disorder, according to results presented at a Psych Congress 2019 poster session.
September 26, 2019
Increased long-term antibody response to cytomegalovirus and decreased long-term antibody response to Toxoplasma gondii were associated with bipolar disorder as well as the subphenotypes of bipolar I.
September 04, 2019
Taking psychiatric medication did not hamper weight loss in people who participated in a structured weight loss program, researchers recently reported online in the journal Obesity. The study compared weight loss outcomes for 17,519 adults enrolled in a lifestyle weight management program at the…
Back to Top